Anemia is common in patients with chronic kidney disease and is associated with a high
burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving …

For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …

In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and
associated with significant adverse consequences. In 2012, Kidney Disease: Improving …

Background Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD) …

Background: Patients with CKD frequently have anemia that results from iron-restricted
erythropoiesis and inflammation. Anemia of CKD is currently managed with iron …

Introduction This integrated phase 3 analysis examined efficacy and cardiovascular safety
for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients …

Results A total of 4277 patients with non–dialysis-dependent CKD were randomized
(roxadustat, n= 2391; placebo, n= 1886). Baseline characteristics were comparable between …

Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Anemia is the predominant cytopenia in myelodysplastic syndromes (MDS) and treatment
options are limited. Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor …

The production of erythropoietin (EPO), the main regulator of erythroid differentiation, is
regulated by hypoxia-inducible factor (HIF). HIF2α seems to be the principal regulator of …